Next Article in Journal
Log P Determines Licorice Flavonoids Release Behaviors and Classification from CARBOMER Cross-Linked Hydrogel
Previous Article in Journal
Electron Beam Radiation as a Safe Method for the Sterilization of Aceclofenac and Diclofenac—The Usefulness of EPR and 1H-NMR Methods in Determination of Molecular Structure and Dynamics
 
 
Communication

Combination of Six Individual Derivatives of the Pom-1 Antibiofilm Peptide Doubles Their Efficacy against Invasive and Multi-Resistant Clinical Isolates of the Pathogenic Yeast Candida albicans

1
Institute of Pharmaceutical Biotechnology, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany
2
Max Planck Institute for Polymer Research Mainz, Ackermannweg 10, 55128 Mainz, Germany
3
Center for Protein Studies, Faculty of Biology, University of Havana, 25 Street, Havana 10400, Cuba
4
Synthetic Peptides Group, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba
5
AIT Austrian Institute of Technology GmbH, Giefinggasse 4, 1210 Vienna, Austria
6
Institute for Medical Microbiology and Hygiene, University Hospital Ulm, 89081 Ulm, Germany
7
Core Facility for Functional Peptidomics, Ulm Peptide Pharmaceuticals (U-PEP), Faculty of Medicine, Ulm University, 89081 Ulm, Germany
8
Core Unit of Mass Spectrometry and Proteomics, Faculty of Medicine, Ulm University, 89081 Ulm, Germany
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Ivana Cacciatore
Pharmaceutics 2022, 14(7), 1332; https://doi.org/10.3390/pharmaceutics14071332
Received: 17 May 2022 / Revised: 14 June 2022 / Accepted: 21 June 2022 / Published: 24 June 2022
In previous studies, derivatives of the peptide Pom-1, which was originally extracted from the freshwater mollusk Pomacea poeyana, showed an exceptional ability to specifically inhibit biofilm formation of the laboratory strain ATCC 90028 as a model strain of the pathogenic yeast Candida albicans. In follow-up, here, we demonstrate that the derivatives Pom-1A to Pom-1F are also active against biofilms of invasive clinical C. albicans isolates, including strains resistant against fluconazole and/or amphotericin B. However, efficacy varied strongly between the isolates, as indicated by large deviations in the experiments. This lack of robustness could be efficiently bypassed by using mixtures of all peptides. These mixed peptide preparations were active against biofilm formation of all the isolates with uniform efficacies, and the total peptide concentration could be halved compared to the original MIC of the individual peptides (2.5 µg/mL). Moreover, mixing the individual peptides restored the antifungal effect of fluconazole against fluconazole-resistant isolates even at 50% of the standard therapeutic concentration. Without having elucidated the reason for these synergistic effects of the peptides yet, both the gain of efficacy and the considerable increase in efficiency by combining the peptides indicate that Pom-1 and its derivatives in suitable formulations may play an important role as new antibiofilm antimycotics in the fight against invasive clinical infections with (multi-) resistant C. albicans. View Full-Text
Keywords: antimicrobial peptides; invasive clinical isolates; combination therapy antimicrobial peptides; invasive clinical isolates; combination therapy
Show Figures

Figure 1

MDPI and ACS Style

Häring, M.; Amann, V.; Kissmann, A.-K.; Herberger, T.; Synatschke, C.; Kirsch-Pietz, N.; Perez-Erviti, J.A.; Otero-Gonzalez, A.J.; Morales-Vicente, F.; Andersson, J.; Weil, T.; Stenger, S.; Rodríguez, A.; Ständker, L.; Rosenau, F. Combination of Six Individual Derivatives of the Pom-1 Antibiofilm Peptide Doubles Their Efficacy against Invasive and Multi-Resistant Clinical Isolates of the Pathogenic Yeast Candida albicans. Pharmaceutics 2022, 14, 1332. https://doi.org/10.3390/pharmaceutics14071332

AMA Style

Häring M, Amann V, Kissmann A-K, Herberger T, Synatschke C, Kirsch-Pietz N, Perez-Erviti JA, Otero-Gonzalez AJ, Morales-Vicente F, Andersson J, Weil T, Stenger S, Rodríguez A, Ständker L, Rosenau F. Combination of Six Individual Derivatives of the Pom-1 Antibiofilm Peptide Doubles Their Efficacy against Invasive and Multi-Resistant Clinical Isolates of the Pathogenic Yeast Candida albicans. Pharmaceutics. 2022; 14(7):1332. https://doi.org/10.3390/pharmaceutics14071332

Chicago/Turabian Style

Häring, Michelle, Valerie Amann, Ann-Kathrin Kissmann, Tilmann Herberger, Christopher Synatschke, Nicole Kirsch-Pietz, Julio A. Perez-Erviti, Anselmo J. Otero-Gonzalez, Fidel Morales-Vicente, Jakob Andersson, Tanja Weil, Steffen Stenger, Armando Rodríguez, Ludger Ständker, and Frank Rosenau. 2022. "Combination of Six Individual Derivatives of the Pom-1 Antibiofilm Peptide Doubles Their Efficacy against Invasive and Multi-Resistant Clinical Isolates of the Pathogenic Yeast Candida albicans" Pharmaceutics 14, no. 7: 1332. https://doi.org/10.3390/pharmaceutics14071332

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop